BullFrog AI Announces Abstract Accepted for Presentation at 2026 ASCO Gastrointestinal Cancers Symposium
MWN-AI** Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has announced that an abstract submitted with Eleison Pharmaceuticals has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, scheduled for January 8-10, 2026, in San Francisco. The research, titled “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma,” will be showcased in Poster Session B on January 9 and will also be published in the ASCO GI 2026 online proceedings and the Journal of Clinical Oncology (JCO) supplement.
The study, co-authored by medical experts from Moffitt Cancer Center and both collaborating companies, focuses on utilizing AI-driven precision oncological techniques to identify distinct patient subtypes that might experience enhanced responses to glufosfamide, an investigational chemotherapy for pancreatic cancer. By leveraging BullFrog AI's bfLEAP® and bfPREP™ platforms, the research aims to analyze complex datasets to reveal biologically meaningful clusters of patients.
Vin Singh, CEO of BullFrog AI, emphasized that the acceptance of this abstract reflects the increasing recognition of AI's transformative potential in oncology research, highlighting how causal AI can uncover vital insights that enhance treatment strategies for challenging cancers like pancreatic adenocarcinoma.
As the date of the symposium approaches, the study's detailed results will remain confidential until the official embargo lifts. BullFrog AI to harnesses AI and machine learning technologies to optimize drug development, aiming to lower clinical trial failure rates. Meanwhile, Eleison Pharmaceuticals is committed to developing drug candidates backed by significant safety and efficacy data, focusing on commercializing therapeutics for patients with life-threatening cancers.
MWN-AI** Analysis
BullFrog AI Holdings, Inc. (NASDAQ: BFRG) has recently made headlines with the acceptance of an abstract for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium. This marks a significant milestone, particularly because it highlights the potential of AI-driven methodologies in oncology, specifically relating to pancreatic adenocarcinoma and the investigational chemotherapeutic agent, glufosfamide. The collaboration with Eleison Pharmaceuticals further validates the efficacy of BullFrog AI's platforms, namely bfLEAP® and bfPREP™, in identifying patient subtypes that may benefit from targeted treatments.
From an investment standpoint, this development could be a pivotal moment for BullFrog AI. The recognition by ASCO serves as a testament to the growing legitimacy and applicability of AI in drug discovery, suggesting potential for enhanced investor confidence. The focus on pancreatic cancer, a notoriously challenging area for effective treatment options, positions BullFrog well in a niche market with substantial unmet medical needs.
With the impact of notable data presentations often leading to increased visibility and potential partnerships, investors should keep a close watch on the outcomes of the poster session scheduled for January 9, 2026. Positive results may boost not only the company's shares but also its chances of securing additional collaborations and funding.
However, stakeholders must remain cautious. As highlighted in the company’s forward-looking statements, various risks could influence performance, including market competition and regulatory hurdles. Monitoring the progression of ongoing studies and partnerships will be essential.
In conclusion, while BullFrog AI showcases substantial promise as an innovator in precision oncology, prudent investors should balance optimism with an awareness of the inherent risks in biotechnology investments. Potential upside could be strong if data validate the ongoing research, making BullFrog AI a stock to watch in the coming months.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
AI-driven precision-oncology analysis identifies patient subtypes with potential enhanced response to glufosfamide
Accepted ASCO abstract, submitted in collaboration with Eleison Pharmaceuticals, provides further validation of BullFrog AI’s technology
GAITHERSBURG, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that an abstract submitted in collaboration with Eleison Pharmaceuticals has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (ASCO GI), to be held January 8–10, 2026, in San Francisco, California.
The abstract, titled “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma,” will be featured in Poster Session B on January 9. It will also be published in the ASCO GI 2026 online proceedings and subsequently appear in the Journal of Clinical Oncology (JCO) supplement corresponding to the symposium.
Co-authored by Richard Kim, MD, Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center, Nikolas Naleid, MD, PharmD, Hematology/Oncology Fellow at Moffitt Cancer Center, Eleison Pharmaceuticals and BullFrog AI, the study explores data-driven precision-oncology approaches to identify patient subtypes that may demonstrate enhanced response to glufosfamide, an investigational chemotherapeutic agent for pancreatic cancer. The research leverages BullFrog AI’s bfLEAP ® and bfPREP™ platforms to analyze complex clinical datasets and uncover biologically meaningful patient clusters.
“This acceptance by ASCO underscores the growing recognition of AI’s ability to transform oncology research,” said Vin Singh, CEO of BullFrog AI. “Our collaboration with Eleison Pharmaceuticals clearly demonstrates how causal AI can help reveal critical insights that guide more precise, effective treatment strategies for difficult cancers like pancreatic adenocarcinoma.”
Results from the study will be presented during the poster session, and in accordance with ASCO’s embargo policy, no additional data will be publicly disclosed until the official embargo lifts prior to the presentation.
About BullFrog AI
BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP ® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
For more information visit BullFrog AI at: https://bullfrogai.com
About Eleison Pharmaceuticals
Eleison’s mission is to acquire and develop drug candidates with existing and significant safety and efficacy data, with the goal of obtaining regulatory approval and commercializing new therapeutics for patients with life-threatening cancers. In addition to its glufosfamide program, the company has two other programs in late-stage clinical development: ILC for small cell lung cancer and pediatric osteosarcoma, and DBD for brain cancers. Eleison has entered development and marketing partnerships with leading pharmaceutical companies in China, South Korea, and Israel. Founded in 2009, Eleison is headquartered in Princeton, NJ.
For more information, visit www.eleison-pharma.com .
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," “could,” “will,” "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
FAQ**
How does BullFrog AI's bfLEAP® and bfPREP™ platforms specifically enhance the identification of patient subtypes for glufosfamide in pancreatic adenocarcinoma, as discussed in the ASCO abstract related to Bullfrog AI Holdings Inc. Warrants BFRGW?
What implications does the acceptance of the ASCO abstract have for BullFrog AI's partnerships with Eleison Pharmaceuticals and their ongoing projects, particularly concerning Bullfrog AI Holdings Inc. Warrants BFRGW?
Can you elaborate on the potential market impact that the findings from the ASCO presentation on glufosfamide and AI-driven precision oncology might have on BullFrog AI Holdings Inc., especially in relation to Bullfrog AI Holdings Inc. Warrants BFRGW?
With the focus on precision oncology and AI, how might BullFrog AI leverage the outcomes of its ASCO presentation for future collaborations or funding opportunities, including the significance of Bullfrog AI Holdings Inc. Warrants BFRGW?
**MWN-AI FAQ is based on asking OpenAI questions about Bullfrog AI Holdings Inc. Warrants (NASDAQ: BFRGW).
NASDAQ: BFRGW
BFRGW Trading
3.45% G/L:
$0.15 Last:
141 Volume:
$0.15 Open:
